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Amphiphilic block copolymers from a renewable ε-decalactone 
monomer: prediction and characterization of micellar core effects 
on drug encapsulation and release 
Deepak Kakde,a Vincenzo Taresco,a Kuldeep K. Bansal,a E. Peter Magennis,a Steven M. Howdle,c 
Giuseppe Mantovani,a Derek J. Irvine*b and Cameron Alexander*a. 
 
Here we describe a methoxy poly(ethyleneglycol)-b-poly(ε-decalactone) (mPEG-b-PεDL) copolymer and investigate the 
potential of the copolymer as a vehicle for solubilisation and sustained release of indomethacin (IND). The indomethacin 
loading and release from mPEG-b-PεDL micelles (amorphous cores) was compared against methoxy poly(ethyleneglycol)-b-
poly(ε-caprolactone)(mPEG-b-PCL) micelles (semicrystalline cores). The drug-polymer compatibility was determined 
through a theoretical approach to predict drug incorporation into hydrated micelles. Polymer micelles were prepared by 
solvent evaporation and characterised for size, morphology, indomethacin loading and release. All the formulations 
generated spherical micelles but significantly larger mPEG-b-PεDL micelles were observed compared to mPEG-b-PCL 
micelles. A higher compatibility of the drug was predicted for PCL cores based on Flory-Huggins interaction parameters (χsp) 
using the Hansen solubility parameter (HSP) approach, but higher measured drug loadings were found in micelles with PεDL 
cores compared to PCL cores. This we attribute to the higher amorphous content in the PεDL-rich regions which generated 
higher micellar core volumes. Drug release studies showed that the semicrystalline PCL core was able to release IND over a 
longer period (80% drug release in 110 h) compared to PεDL core micelles (80% drug release in 72 h). 
Introduction 
The poor solubility of active drugs in aqueous environments is one of 
the major hurdles to the development of improved formulations.1 It 
has been estimated that around 70% of new therapeutic chemical 
entities are poorly soluble in aqueous media.2 Consequently, the use 
of micelles has emerged as one of the major strategies to achieve 
enhanced solubilisation and controlled release of hydrophobic 
drugs.3-8 Micelles of interest in drug delivery are nanoscale structures 
(10-100 nm) obtained by the self-assembly of interfacially active, 
amphiphilic molecules (an emulsifier) upon their addition to water. 
The hydrophobic part of the micelle forms the self-assembled core 
which is surrounded by a hydrophilic outer shell, often referred to as 
the corona.9 This core-shell structure creates a cargo space for 
hydrophobic molecules that enables drug transportation.10, 11 
Increasingly, polymeric emulsifiers are being used to create micellar 
drug carriers due to the higher levels of interfacial stability that they 
exhibit when compared to small molecule interfacial agents. With 
polymeric emulsifiers, the drug loading that is achieved in such the 
cargo spaces can be affected by various factors, including the 
chemical nature of the particular core-forming block, the relative 
block length, the overall polymer molecular weight, the properties of 
the drug involved, and the level of drug-polymer compatibility.12 A 
significant number of studies have shown that drug-polymer 
compatibility is one of the major factors in determining the level of 
loading obtained.13, 14 For example, Yang et al. showed enhanced 
doxorubicin loading in acid-functionalized polycarbonate block 
copolymers due to the electrostatic interaction between the amine 
group of the drug with the acid group of the polymer.15 However, 
strong interactions such as these can also adversely delay drug 
release from the core. Therefore, it is just as important that a 
formulation should be optimised to exhibit desirable release kinetics. 
To achieve this, several research groups have focused on the use of 
block copolymers containing specific functional groups for which the 
interaction with the drug can be manipulated via alteration of the 
system conditions e.g. temperature, pH and redox.16-20 By adopting 
this strategy improvements to drug stability, loading and release 
characteristics have been achieved for amphotericin B,21 cisplatin,22 
and doxorubicin.23, 24  
One of the key methods used to determine drug-polymer 
compatibility is via Flory-Huggins interaction parameters,11, 12, 25, 26, 21 
where a low value for the parameter (i.e. approaching zero) predicts 
a strong interaction between drug and polymer. A second important 
series of factors that have been shown to influence drug-polymer 
interactions are the physical/material properties of the copolymer 
amphiphiles. In general, micelles which possess amorphous cores are 
able to accommodate higher drug loadings. It has been proposed 
that this is because the drug molecules reside only in the amorphous 
region of the polymer.12, 27 Accordingly, there is a need for drug 
delivery polymers which have the appropriate physical properties to 
prevent core crystallisation. At the same time, there has been an 
increasing focus on utilising materials which are obtained from 
natural sources and synthesised using sustainable chemistries.28-33 
This study has investigated replacing ε-caprolactone (ε-CL, see Figure 
1) with monomers which are not obtained from petrochemical 
sources, and which may be advantageous as drug delivery materials 
also because they are not semi-crystalline in nature. Here we show 
that ε-decalactone (ε-DL, see Figure 1) is a good alternative to ε-
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caprolactone as a biomedical monomer because; (a) the (ε-DL) 
monomer is derived from a sustainable source, i.e. castor oil, (b) it 
has already been commercially adopted in the flavouring and 
fragrance industries,34, 35 and (c) the pendent butyl groups are 
predicted to disrupt the chain packing of PεDL chains, so promoting 
the desired amorphous character within the poly(ε-decalactone) 
(PεDL) core structures to enhance drug loading.36 We thus describe 
the synthesis of novel mPEG-b-PεDL block copolymers and 
determine the efficiency of drug loading and the release profiles of 
drugs from mPEG-b-PεDL micelles. These data are compared to the 
current benchmark methoxy poly(ethyleneglycol)-b-poly(ε-
caprolactone) (mPEG-b-PCL) micelles. Additionally, the drug-micelle 
core compatibilities are assessed and compared to the drug loading 
and release pattern experimentally achieved. The synthetic strategy 
for the copolymers is given in scheme 1. 
 
Figure 1 Structure of ε-decalactone (ε-DL, renewable) and ε-
caprolactone (ε-CL , non-renewable) monomers 
 
 
Scheme 1 Synthetic route utilised to synthesise the amphiphilic block copolymers which were used to generate micelles with 
different core properties. 
Experimental Section 
Materials 
-Decalactone (ε-DL)   (≥99%), -caprolactone (-CL), (97%), 1,5,7-
Triazabicyclo[4.4.0]dec-5-ene (TBD)  (98%), mono methoxy 
poly(ethylene glycol) (Mn 5000) (mPEG), benzoic acid  (≥99.5%), 
indomethacin (≥99%) (IND), were all purchased from Sigma-Aldrich. 
All solvents were purchased from Fischer Scientific UK. All chemicals 
were used as received unless otherwise stated. Azeotropic 
distillation was used for dehydration of mPEG using anhydrous 
toluene. 
Methods 
Synthesis of PεDL homopolymer: The PεDL homopolymer was 
synthesised via ring opening polymerisation (ROP) of ε-DL utilising 
benzyl alcohol as the initiator and Triazabicyclo[4.4.0]dec-5-ene 
(TBD) as the catalyst. In a typical procedure, benzyl alcohol (0.04 g, 
0.42 mmol) was transferred into a flask containing ε-DL (5.00 g, 29.37 
mmol) monomer and the mixture was stirred for 5-10 minutes at 120 
oC to produce a homogeneous mixture. A quantity of TBD (0.12 g, 
0.88 mmol) was dissolved in anhydrous acetone (0.5 mL) and then 
added to the flask under a nitrogen atmosphere and the acetone was 
evaporated via nitrogen degassing (10 minutes). The reaction was 
then allowed to proceed at 120 oC for 12 hours with stirring. The 
reaction was then quenched by the addition of benzoic acid (0.21 g, 
1.76 mmol) and cooled. The resulting product was purified by 
precipitation into cold methanol, and the residual solvent was 
removed under vacuum. The final product was a colourless, viscous 
oil obtained in a 74% (3.73 g) yield.  
1H NMR (400 MHz, CDCl3) δ (ppm) 7.36 (Benzene protons, m, 5H), 
5.12 (CH2-O-CO, s, 2H), 4.87 (CH-O-CO, m, 62H), 2.28 (O-CO-CH2, t, 
127H), 1.63-1.54 (CH2-CH2-CH2-CH (OCO)-CH2, m, 386H), 1.30 (CH-
CH2-CH2; CH3-CH2-CH2, m, 391H), 0.89 (CH2-CH3, t, 191H). 
13C NMR (101 MHz, CDCl3) δ (ppm) 173.25 (O-CO-CH2), 136.06 (C-
CH2-O, ring carbon), 128.53 (CH-CH-CH-C , ring carbon), 128.16 (CH-
ε-Caprolactone
(Non-renewable)
ε-Decalactone
(Renewable)
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 201X, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
CH-CH-C , ring carbon),  73.87(CH2-CH-O), 66.10 (CH2-O-CO), 34.48 
(CH2-CH- CH2), 33.72 (O-CO-CH2), 27.45 (CH-CH2-CH2), 25.00 (CO-CH2-
CH2), 22.56 (CH-CH2-CH2; CH3-CH2-CH2), 13.98 (CH3-CH2-CH2). FTIR 
(cm−1): 2932 (C–H, stretching, aromatic), 2862 (C–H, stretching, 
methylene), 1727 (C=O, stretching), 1345 (C–H, bending), 1097 (C–
O, stretching). 
Synthesis of mPEG-b-PεDL and mPEG-b-PCL block copolymers: This 
procedure followed that detailed for the homopolymerisation but 
mono methoxy poly(ethylene glycol) (mPEG) (Mn 5000) (2.44 g, 0.49 
mmol) was used as the initiator.  The mPEG was reacted with ε-DL 
(5.00 g, 29.37 mmol) to generate the mPEG-b-PεDL copolymers and 
ε-CL (2.78 g, 24.4 mmol) for the mPEG-b-PCL. The resultant polymer 
was precipitated into cold methanol three times, followed by 
evaporation of the residual solvent under vacuum. This crude 
polymer product was dissolved in minimum volume of acetone and 
re-precipitated into diethyl ether three times. Any solvent residues 
were removed under vacuum. The product mPEG-b-PεDL copolymer 
was a waxy colourless solid and was obtained in a 68% (5.02 g) yield.   
 
1H NMR (400 MHz, CDCl3) δ (ppm) 4.87 (CH-O-CO, m, 36H), 4.24 (CH2-
O-CO, t, 2H), 3.66 (O-CH2-CH2-O, s, 487H), 3.40 (O-CH3, s, 3H), 2.29 
(O-CO-CH2, t, 75H), 1.61-1.55 (CH2-CH2-CH2-CH (OCO)-CH2, m, 230H), 
1.31 (CH-CH2-CH2; CH3-CH2-CH2, m, 234H), 0.90 (CH2-CH3, t, 116H). 
13C NMR (101 MHz, CDCl3) δ (ppm) 173.25 (O-CO-CH2), 73.86(CH2-
CH-O), 70.57 (CH2-CH2-O), 34.48 (CH2-CH- CH2), 33.80 (O-CO-CH2), 
27.44 (CH-CH2-CH2), 24.99 (CO-CH2-CH2), 22.55 (CH-CH2-CH2; CH3-
CH2-CH2), 13.98 (CH3-CH2-CH2). 
FTIR (cm−1): 2880 (C–H, stretching), 1731 (C=O, stretching), 1341 
(C–H, bending), 1102 (C–O, stretching). 
The mPEG-b-PCL product was solid off-white in colour with 89% 
(10.54 g) yield. 
1H NMR (400 MHz, CDCl3) δ (ppm) 4.24 (CH2-O-CO, t, 2H), 4.08 (CH2-
O-CO, t, 92H), 3.66 (O-CH2-CH2-O, s, 464H), 3.40 (O-CH3, s, 3H), 2.33 
(O-CO-CH2, t, 93H), 1.67 (CH2-CH2-CH2, m, 211H), 1.40 (CH2-CH2-CH2, 
m, 91H).  
13C NMR (101 MHz, CDCl3) δ (ppm) 173.50 (O-CO-CH2), 70.58 (CH2-
CH2-O), 64.13 (CH2-O-CO), 34.12 (O-CO-CH2), 28.36 (CH2-CH2-O-CO), 
25.53 (CH2-CH2-CH2), 24.58 (CO-CH2-CH2). 
FTIR (cm−1): 2886 (C–H, stretching), 1723 (C=O, stretching), 1342 
(C–H, bending), 1100 (C–O, stretching) 
Polymer Characterisation 
Nuclear Magnetic Resonance: A Bruker NMR spectrometer operating 
at 400 MHz (1H) and 101 MHz (13C) was used to perform nuclear 
magnetic resonance (NMR) analysis on the purified polymers in 
deuterated solvents. Chemical shifts were assigned in parts per 
million (ppm). MestReNova 6.0.2 copyright 2009 (Mestrelab 
Research S. L.) was used for analysing the spectra. 
Determination of Monomer Conversion by 1H NMR: In ε-DL 
polymerisations the conversion was assessed by comparing the peak 
area integral of –O–CH(C4H9)– (proton attached to ε-carbon; δ= 4.19 
ppm) of ε-DL monomer to the integral of the same peak within the 
PεDL polymer (PεDL; δ= 4.87 ppm) in the 1H NMR spectrum. Figure 
S1 shows the spectra before and after conversion of the ε-DL 
monomer via polymerisation. In ε-CL based reactions the integral 
intensity of –O–CH2– (δ= 4.14 ppm) for the ε-CL monomer was 
compared to the intensity of the same peak for PCL polymer (δ= 4.08 
ppm) (Figure S2). 
Determination of the degree of polymerisation (DP) in the homo- and 
copolymers by 1H NMR: In the case of ε-DL, the degree of 
polymerisation was estimated by comparing the peak area integrals 
of benzyl protons (C6H5-, δ=7.36 ppm) and methoxy protons (–O–
CH3, δ=3.40 ppm) in the benzyl alcohol and mPEG initiators 
respectively with that of the –O–CH(C4H9)– (δ=4.87 ppm) proton 
peak in the PεDL purified polymer (Figure S3, S4).  
The calculated molecular weight of mPEG-b-PεDL copolymer by 1H 
NMR was found to be 11,100 g/mol which was lower than the 
predicted molecular weight of 15200 g/mol  based on the feed ratio 
of M/I = 60 used during the synthesis (Figure S4).  
In the 1H NMR spectrum of mPEG-b-PCL (Figure S5), the degree of 
polymerisation (DP) was determined for the purified polymer by 
comparing the integral of mPEG (–O–CH3, δ=3.40 ppm) to that of PCL 
(–O–CH2–, δ=4.08 ppm). The calculated molecular weight of mPEG-
b-PCL copolymer was 10,250 g/mol in good agreement with the 
predicted molecular weight of 10700 g/mol (Figure S5). 
Further spectroscopy (13C NMR) was used to determine the purity of 
the homopolymer and copolymer of ε-DL (Figure S6 and S7) and 
copolymer of ε-CL (Figure S8). 
Gel permeation chromatography (GPC): was used for determination 
of number-average molecular weight (Mn), weight average 
molecular weight (Mw), peak molecular weight (Mp) and molecular 
weight distribution (polydispersity, Ð, Mw/Mn). The analysis was 
performed on a Polymer Laboratories GPC 50 instrument fitted with 
a differential refractive index detector. HPLC grade CHCl3 was used 
as eluent at a flow rate of 1 mL/min.  A calibration curve was made 
using polystyrene standards (Mw range: 443000-132 g/mol) and 
Polymer Labs Cirrus 3.0 software was used for data analysis.  
Differential scanning calorimetry (DSC): The thermal properties of 
the materials were measured using TA-Q2000 DSC (TA Instruments). 
Samples were subjected to two heating-cooling cycles from -90 to 
150 oC at 10 oC/min and the second cycle results were reported.  
Fourier transform infrared spectroscopy (FTIR): FTIR spectroscopy 
was performed in the range of 4000-650 cm-1 by placing a small 
quantity of the sample on a clean ATR crystal in the sample holder of 
a Cary 630 FTIR spectrophotometer. Spectra were analysed using 
MicroLab software.  
Determination of solubility parameters: The drug–micellar core 
compatibility was calculated using the Flory-Huggins interaction 
parameter which is given by: 
χsp = (δs-δp)2 Vs/RT                            (equation 1) 
Where χsp = Interaction parameter of solubilizate (drug) and core 
forming block (polymer hydrophobic block); δs = Solubility parameter 
of solubilizate; δp = Solubility parameter of the polymer (core block); 
Vs = Molar volume of solubilizate; R = Gas constant and T 
temperature in Kelvin. The partial solubility was calculated using the 
group contribution method (GCM) obtained by the Hoftyzer Van 
Krevelen method for the estimation of solubility parameter.37 The 
systematic, stepwise calculations for determining various 
parameters are given in supporting information Table S1. 
Self-assembly of block copolymers and characterisation of micelles: 
Micelles of the block copolymers were prepared by dissolving the 
block copolymer (50 mg) in acetone (5 mL) and adding the solution 
at a fixed rate of 0.5 mL/min into HPLC grade water (10 mL) with 
stirring (1000 rpm). The solution was stirred for 4 hours at room 
temperature and then left overnight (open in fume hood) for 
complete removal of acetone. The micellar solutions were then 
filtered through a membrane syringe filter (pore size: 220 nm) 
(Millex-LG, Millipore Co., USA) to remove any aggregates. Size and 
size distribution of prepared micelles were determined by dynamic 
light scattering (DLS) using a polymer concentration of 0.5 mg/mL in 
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HPLC grade water. Zetasizer software version 7.03 was used for data 
analysis. The morphology of the micelles was investigated by 
transmission electron microscopy (TEM) using a Tecnai G2 (FEI, 
Oregon, USA) microscope. A droplet of micelle solution (10 µL) 
containing 1 mg/mL of the polymer was placed on the copper grid 
and allowed to dry in air.  Samples were then imaged at 100 KV using 
TIA imaging software, without staining, at a magnification of ×43000.   
Assessment of drug loading within micelles: The copolymer micelles 
were formed by a single step nanoprecipitation method and purified 
as described previously38 but in this case both copolymers (50 mg) 
and IND (4 mg) were dissolved in the acetone (5 mL) feedstock to be 
added into HPLC grade water (10 mL). The drug-loaded micelles were 
then passed through a PD10 desalting column to remove any free 
drug prior to further characterisation. A portion of the obtained 
micellar solution was then freeze-dried to estimate the drug content 
(wt%) and encapsulation efficiency (%EE). The amount of 
indomethacin loaded in the micelles was determined by dissolving a 
known amount of micelles (5 mg) in methanol and comparing the 
data collected by a UV-visible spectrophotometer at λmax = 318 nm to 
a calibration curve which had been constructed over the 
quantification range of 5-50 μg/mL (Beckman Coulter DU 800 UV 
spectrophotometer).39 The calculation for the drug content (wt%) 
and encapsulation efficiency (%EE) was performed as described in 
the literature by using the formula.40 
Drug Content (wt%) = Total amount of drug in the micelles (in mg)  X 
100 / Total amount of micelles (mg) 
% Encapsulation Efficiency (%EE) = Total amount of drug in the 
micelles (in mg) X 100 / Total amount of drug added (mg) 
In-vitro drug release study from the micelles: Analysis of the in-vitro 
release of IND was performed based upon a reported method39 with 
the following modifications. An appropriate amount of freeze-dried 
micelles, with a drug content equivalent to 250 μg of IND was 
dispersed in HPLC grade water (1 mL). The solution was transferred 
to dialysis tubing (Slide-A-Lyzer, 3.5 kDa, Thermo Scientific) and 
dialysed against 5 mL of phosphate buffer solution (PBS, 0.1 M, pH 
7.4) at 37 oC. At predetermined time intervals, the whole release 
media was taken as a sample and replaced with fresh media to 
maintain sink conditions. The samples were then freeze-dried and 
dissolved in methanol (1 mL) for quantification by UV-visible 
spectroscopy. Three control solutions (Control ‘A’, ‘B’ and ‘C’) were 
also prepared for comparison and analysed by the same method 
given above. Control solution ‘A’ consisted of 250 μg of IND dissolved 
in 1 mL of phosphate buffer. Control solution ‘B’ consisted of 250 
μg/mL of IND in PBS to which 15 μL of mPEG-b-PεDL copolymer 
solution in acetone (250 mg/mL of mPEG-b-PεDL) was added. Control 
solution ‘C’ consisted of 250 μg/mL of IND in PBS to which 18 μL of 
mPEG-b-PCL copolymer solution in acetone (250 mg/mL of mPEG-b-
PCL) was added. The acetone in control solutions (Control ‘B’ and ‘C’) 
was removed by bubbling with nitrogen, and the volume was made 
up to 1 mL, if required. 
Statistical analysis. Data were reported as mean ±standard deviation 
(SD). Statistical analysis for the significant difference was performed 
using Student’s unpaired t-test. A significance level was set at P 
<0.05. 
Results  
Synthesis and characterization of polymers 
The molecular characterisation data for the homopolymer and block 
copolymers PεDL are shown in Table 1. The optimum concentration 
of the TBD catalyst was found to be 3 mol% and was used for all the 
polymerisations. At this concentration >85 % conversion of ε-DL was 
achieved within 12 h. Figure 2 shows the results of a typical 
polymerisation kinetics experiment as a plot of both the log of 
monomer conversion and conversion as a percentage against time. 
The linear relationship demonstrated in Figure 2 indicates that the 
reaction followed pseudo-first order kinetics, and the apparent rate 
constant (kp) of ε-DL polymerisation was determined from this data 
to be 0.18 h-1. Homopolymer and other impurities in the product (as 
detected by GPC analysis of the unpurified mPEG-b-PεDL copolymer) 
were removed by methanol precipitation and diethyl ether re-
solvation cycles. The GPC chromatogram of the pure copolymer 
showed a unimodal size distribution with low polydispersity (Figure 
S9). GPC-determined molecular weights underestimated the Mn of 
homopolymer and overestimated the Mn for copolymer when 
compared to values calculated by 1H NMR (Table 1). These 
discrepancies were most likely due to the differences in solubility 
behaviour and solution conformation of the tested polymers 
compared to the polystyrene standards. 
 
 
Figure 2 Kinetic analysis of ε-decalactone polymerisation on mPEG5K 
at 120 oC using TBD as a catalyst (conversion determined by 1H NMR) 
 
 
Table 1 Molecular characteristics of mPEG5K, PεDL homopolymer and block copolymers determined by 1H NMR and GPC. 
Polymera 
[M]/[I] 
Ratiob 
Predicted 
Mol. Wt. 
(g/mol) 
Mn by 
1H NMR 
(g/mol) 
GPC (g/mol) 
Mn Mw Mp PDI 
mPEG5K -- 5000 --- 9400 9700 9400 1.03 
PεDL62 70 12000 10700 6100 11300 10100 1.86 
mPEG-b-
PεDL36 
60 15200 11100 15000 16300 15000 1.08 
mPEG-b-PCL46 50 10700 10250 17000 25200 17600 1.48 
a The number in subscript shows degree of polymerisation of each block; b Monomer/Initiator ratio in feed; Mn: Number average molecular 
weight, Mw : Weight average molecular weight, Mp: Peak molecular weight (Mp), PDI: Polydispersity index  
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Table 2 DSC analysis of homopolymers and copolymers 
Polymer Tg  (oC) Tm (oC) 
Melting 
Enthalpy 
(∆H) J/g 
Hydrophobic 
block 
mPEG5K --- 65 201 --- 
PCL5K -56 60 96 Semicrystalline 
PεDL -53 --- --- Amorphous 
mPEG-b-
PεDL 
-52 57 86 Amorphous 
mPEG-b-
PCL 
-57 60 114 Semicrystalline 
Tg: Glass transition temperature, Tm: Melting Temperature 
 
DSC analysis was conducted on the copolymers, and the data are 
shown in Table 2. PCL is a semi-crystalline polymer (Tg -60 ⁰C and Tm 
59-64 ⁰C), and it has been established that typically the crystallinity 
of polymers decreases with increasing the molecular weight.41 The 
reference PCL5K homopolymer displayed both a Tg and Tm in the DSC 
scan indicating semi-crystalline behaviour. The DSC of the PεDL 
homopolymer reported only a Tg indicating the amorphous nature of 
the homopolymer which was consistent with previous reports.27 The 
block copolymer data showed that the presence of mPEG imparted 
a level of crystallinity to PεDL copolymers as both Tg and Tm were 
apparent in DSC scans (Figure S10). As apparent from table 2 it is 
likely that there was some core crystallinity in the PCL containing 
block copolymer as both blocks exhibited semi-crystalline behaviour. 
Ring-opening polymerisation of ε-CL from mPEG resulted in full 
conversion to polymer within 15 min. The lower reaction time of CL 
compared to DL was attributed to the higher reactivity of the non-
side-chain substituted monomer. The calculated molecular weight of 
the copolymer was 10250 g/mol compared to the theoretical 
molecular weight of 10700 g/mol indicative of a controlled 
polymerisation (Table 1).  
Self-assembly of block copolymers and micelles structure. 
Both empty and indomethacin (IND)-loaded micelles were prepared 
by nanoprecipitation. IND was chosen as a model drug for the 
incorporation studies because controlled release oral formulations 
for this important hydrophobic non-steroidal anti-inflammatory drug 
(NSAID) are in widespread clinical use to avoid acute toxicity and 
because analytical methods for its loading and release have been 
well-established.42 The percentage recovery of the mPEG-b-PεDL and 
mPEG-b-PCL copolymers micelles after freeze-drying was found to be 
91% and 93% respectively. The self-assembling properties of the 
copolymers were evaluated via DLS in HPLC grade water. A significant 
difference was observed between the sizes of the mPEG-b-PCL and 
mPEG-b-PεDL micelles.  The average diameter (Z-average diameter) 
of mPEG-b-PεDL micelles was ~38 nm while that of the mPEG-b-PCL 
micelles was observed to be ~30 nm (Table 3).  
 
These data correlated with previous reports for ε-caprolactone and 
δ-decalactone based copolymers where micelle sizes in the range of 
30-40 nm were found.38 No secondary size distributions were 
recorded for either of the micellar formulations and the TEM images 
of the micelles showed uniform spherical micelles with a clear 
surface boundary. Analysis of TEM images using ImageJ software 
suggested a larger mean size (i.e. <60 nm) than recorded by DLS for 
both of the micelles formulations, although there was no sign of 
aggregation in either case (Figure 3). The difference between the 
sizes of the micelles as recorded by the different techniques may 
have been due to the collapse of the spherical micelles into ‘pancake’ 
structures on dehydration prior to TEM. The data from Table 3 
indicate that there were no significant differences between the drug 
loaded and unloaded micelles of both the mPEG-b-PCL and mPEG-b-
PεDL copolymers (P > 0.05, unpaired student’s t-test), although there 
was a significant difference in the average size of the micelles of the 
different copolymers (P < 0.05, unpaired student’s t-test). In 
addition, there were still significant differences in the average 
micellar sizes of the different copolymers after drug loading into the 
micelles (P < 0.05, unpaired student’s t-test). The optimum 
drug:polymer ratio for the nanoprecipitation was found to be 4:50 
and was used for both formulations. A significant difference in 
percentage encapsulation was observed between the copolymers. 
For the mPEG-b-PεDL micelles, 81% of the IND was encapsulated 
compared to only 66% in the mPEG-b-PCL micelles which translated 
into a significant difference in drug loading between the two 
polymers. The mPEG-b-PεDL micelle was able to load around 6.5 wt% 
of IND whereas only 5.4 wt% was loaded by mPEG-b-PCL micelles (P 
< 0.05, unpaired student’s t-test Table 3). 
The percent cumulative release profile of IND against time for 
different formulations and control systems is shown in Figure 4. 
Control ‘A’ contained drug dissolved in PBS and showed rapid transit 
of IND, with more than 90 percent of the free drug able to cross the 
dialysis membrane within 12 h. In contrast to the rapid release 
observed in Control ‘A,' when IND was mixed with empty micelles of 
mPEG-b-PεDL (Control ‘B’) or of PEG-b-PCL (Control ‘C’) in PBS, transit 
of the drug across the membrane was not complete until after > 24 
h. Nevertheless, nearly 90% of the IND was recovered within 24 h 
from both control ‘B’ and ‘C’. No significant difference was observed 
between control ‘B’ and control ‘C’ formulations. In contrast, IND 
encapsulated in the polymer micelles was released at a much lower 
rate, with a time period of ~ 120 h for 80% IND to cross the dialysis 
membrane. 
 
Table 3 Characteristics of empty and IND loaded block copolymer micelles 
Polymera 
Empty micelle  
Drug 
Content 
(wt%) ± SD 
 
Encapsulation 
Efficiency 
 (%EE)± SD 
IND loaded micelles 
Average Size 
(nm)b 
PDIc Average size (nm)b PDIc 
mPEG-b-PεDL36 38 ± 4d 0.16 ± 0.02 6.55 ± 0.17 d 81.10 ± 6.32c 39 ± 5 0.21 ± 0.02 
mPEG-b-PCL46 30 ± 3 0.18 ± 0.01 5.39 ± 0.49 66.14 ± 9.26 32 ± 4 0.20 ± 0.02 
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a The number in subscript shows degree of polymerisation of each block. b Determined from intensity mean by Dynamic Light 
Scattering (DLS) Technique. C Polydispersity index (PDI) by Dynamic Light Scattering (DLS) Technique. d Significant difference 
from mPEG-b-PCL46 (P < 0.05, unpaired student’s t-test). 
 
 
 
Figure 3 Micelle Size distributions by DLS, TEM Image and size distribution histogram (using Image J software) of empty (A) mPEG-b-PεDL 
micelles, (B) mPEG-b-PCL micelles. The images were taken without staining. Scale bar – 1000 nm. 
 
Figure 4 (A) Indomethacin loading (wt% to polymer) in different copolymers. (B) In-vitro IND release (%) from different test formulations 
in pH 7.4 PBS buffer solution at 37 oC 
 
 
Furthermore, whilst the release rate profiles were similar for IND-
loaded mPEG-b-PεDL and mPEG-b-PCL micelles, a significant 
difference was observed in the quantity of IND released with time 
from the respective co-polymers. Both systems showed an initial 
rapid release which was followed by a sustained release phase. The 
mPEG-b-PεDL micelles exhibited an initial burst of 34% IND release 
in 6 h. This was then followed by a sustained release phase (92% in 
120 h) where drug slowly diffused across the dialysis membrane into 
the release media. The mPEG-b-PCL micelles were able to release the 
drug more slowly with 25% of the IND ‘dose’ released in the first 6 h 
followed by 85% drug release in 120 h.  
Determination of solubility parameters and interaction parameters 
of indomethacin with copolymers 
The solubility parameters of IND, the mPEG block and the 
hydrophobic blocks (PεDL and PCL) were calculated using the Hansen 
solubility approach (see equation 1 in experimental section). The 
calculated values are presented in Table 4 and indicate that the Van 
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der Waals dispersion forces were similar for all the copolymer 
segments. Meanwhile, the polarity and hydrogen bond formation 
ability was noted to be higher for the PEG segment.  The solubility 
difference (δs-δp) was calculated using the partial solubility data. The 
lowest value of this parameter was found for the PCL core (PCL = 
4.47) (Table 5). The interaction parameter (χsp) was then determined 
using the (δs-δp) value from equation 1. The values for the solubility 
differences and interaction parameters are given in table 5. The 
interaction parameters were predicted to be in the order of χsp 
(PεDL)> χsp (mPEG)> χsp (PCL). The lower interaction parameter value 
for PCL suggested a higher compatibility with this drug. Hence, the 
PCL block was predicted to encapsulate more IND compared to the 
other copolymers synthesised for this study. 
Table 4 Calculated value of partial solubility and total solubility 
parameters of copolymer segments and drug 
Polymer 
segments 
and drug 
Partial solubility 
parameter (MPa1/2) 
Molar 
Volume 
(cm3/mol) 
Total 
Solubility 
Parameter     
δT  (MPa1/2) δd δp δh 
PεDL 17.05 3.00 6.54 163.20 18.50 
PCL 17.66 4.97 8.42 98.50 20.18 
PEG 17.17 11.11 9.12 36.00 22.85 
Drug (IND) 21.80 6.00 9.40 230.00 24.50 
δd dispersion parameter; δp dipolar parameter; δh hydrogen 
bonding parameter; δT total solubility parameter. 
 
Table 5 Calculated values of solubility difference (δs-δp) and 
interaction parameter χsp between drug and polymer segments 
Drug 
(δs-δp)  
or ∆ 
(PEG)a 
(δs-δp)  
or ∆           
(PCL)b 
(δs-δp)  
or ∆           
(PεDL)c 
χsp 
(PEG)d 
χsp 
(PCL)e 
χsp 
(PεDL)f 
IND 6.51 4.47 6.30 3.39 1.85 3.68 
Solubility difference between a drug and mPEG; b drug and PCL; c 
drug and PεDL. Flory-Huggins interaction parameter between d 
drug and mPEG; e drug and PCL; f drug and PεDL. 
Discussion 
The commercial availability, renewability and structural similarity 
with ε-CL (currently regarded as a non-renewable feedstock) makes 
ε-DL a versatile monomer for polymer synthesis. The TBD catalyst 
offered a fast reaction under mild conditions, potentially conferring 
advantages over Sn(Oct)2 which has been extensively used in ROP 
previously.43-45 The DSC data demonstrated that the alkyl side chains 
of ε-DL disrupted the packing in the PεDL block compared to PCL 
blocks, generating mPEG-b-PεDL micelles with amorphous cores. The 
finding that PεDL homopolymer was amorphous was also supported 
by previous studies.27, 36 
Here we targeted the block copolymer synthesis to produce an 
overall hydrophilic: hydrophobic ratio of 1:1 in order to control the 
core properties of the micelles. The initial polymerisations were 
conducted at low concentrations of TBD (i.e. 1 and 2 mol% TBD 
compared to monomer), and this resulted in low conversion of ε-DL. 
However, after [TBD] was increased to 3 mol%, approximately 85% 
of the ε-DL was converted into PεDL within 12 h. In a comparable 
polymerisation, the ε-CL monomer was converted to PCL within 15 
min (>90% conversion) using 3 mol % TBD. These results were 
attributed to the presence of the butyl side chain on the ε-DL. The 
additional steric bulk of this functional group reduced the reactivity 
of the secondary alcohol in the ROP process. The lower reactivity of 
ε-DL has been previously described by Olsen et al.46  Additionally, the 
initiation efficiency was also observed to be lower for ε-DL 
polymerisation for the same reason. Thus a higher monomer to 
initiator ratio of [M]:[I]= 70 and 60 respectively were required for 
homopolymers and copolymer to achieve the target molecular 
weights. 
The Gel Permeation Chromatography (GPC) data were found to 
underestimate the Mn of PεDL homopolymer compared to the Mn 
determined by 1H NMR. This was most likely to have been a result of 
the less favourable solvation in chloroform of the PεDL polymer 
compared to the GPC standards, resulting in suppression of 
hydrodynamic volume of the polymer. The underestimation of Mn in 
GPC has been reported previously.46 In contrast to the 
homopolymer, the Mn of the copolymer was overestimated (Table 
1), again likely due to differences in solvation with the calibrant 
polymer and this too was consistent with previous reports.27 The 
polydispersity index (PDI) determined by GPC provides valuable 
information regarding the polymer size distributions. Low 
polydispersities determined by GPC for both of the copolymers 
suggested some control over the chain lengths of the copolymers. In 
contrast, higher polydispersities of the homopolymers were 
observed indicating loss of polymerisation control, most likely due to 
the presence of nucleophilic or basic impurities such as adventitious 
water in the reaction. It was found to be difficult to separate benzyl 
alcohol initiated homopolymers from other homopolymers (initiated 
by impurity nucleophiles) due to the lack of differences in solubility 
and molecular weight. However, the desired copolymers were easily 
separated from homopolymer by precipitation in diethyl ether, in 
which solvent the homopolymer remained in solution. 
Both of the copolymers were similar in terms of molecular weight, 
however, the mPEG-b-PCL copolymer contained approximately 46 
caprolactone units attached to mPEG as calculated from NMR 
integrals whereas ~ 36 units of ε-DL were contained in the mPEG-b-
PεDL copolymer. As a consequence, in the absence of solvation 
effects, the hydrophobic main-chain block should have generated a 
greater end-to-end distance for the PCL co-polymer compared to the 
PεDL copolymer. In turn, a longer hydrophobic chain in the 
copolymer was expected to produce micelles of larger size. By 
contrast, smaller micelles were produced from the mPEG-b-PCL 
copolymer (30 ± 3 nm) compared to the mPEG-b-PεDL copolymer (38 
± 4 nm), indicating that solvation and chain packing in the micellar 
cores was an important factor. The presence of the extra alkyl side 
chains on the PεDL block of the mPEG-b-PεDL copolymer most likely 
induced greater disorder in the cores and a higher volume. This 
assertion was supported by the amorphous nature of the PεDL core 
reported in DSC thermograms, as the lack of extended molecular 
order enabled the core to occupy a larger volume compared to the 
semicrystalline PCL core. The alkyl chain was also expected to 
increase the hydrophobicity of the PεDL core, and also to change the 
extent of interaction with hydrophobic drugs. However, no 
significant difference in size was observed before and after loading 
of the model drug indomethacin in the micelles, suggesting that 
polymer-drug interactions were not predominant over polymer-
polymer association. A single sharp peak in the DLS was observed for 
both the copolymers and confirmed the narrow size range of the 
micelle formulations. The morphology of the micelles was also 
studied by TEM, which showed smooth, spherical micelles that were 
well separated from each other, indicating good stability against 
aggregation for these micelles. This behaviour would suggest that 
these micelles may not aggregate upon being injected into the 
circulation in a drug delivery application. It is well known that small 
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(10 – 200 nm in diameter) and surface-hydrated micelles are less 
susceptible to uptake by the RES system,47 and thus the obtained 
polymer micelles might be predicted to have good in vivo stability 
and thus long circulation time if injected systemically.  
In order to predict drug loadings with these co-polymers, 
investigation of polymer-drug interactions via Flory-Huggins theory 
was carried out. This parameter has been used in a number of studies 
for the prediction of drug solubility in polymers.48-51 In one prior 
investigation,13 the Flory-Huggins interaction parameter (sp) was 
calculated between the drug cucurbitacin I with poly(ε-caprolactone) 
(PCL), poly(-benzylcarboxylate-ε-caprolactone) (PBCL) and poly(-
cholesteryl carboxylate-ε-caprolactone) (PChCL) blocks of specific 
copolymers to determine the compatibility of the drug in the micellar 
cores. A higher drug-polymer compatibility was predicted for PChCL 
core micelles, which was also supported by the drug encapsulation 
study on the mPEG-b-PChCL micelles. The authors suggested that the 
addition of a cholesteryl moiety to produce PChCL blocks improved 
the solubilization of the cholesteryl compatible cucurbitacin drug in 
the mPEG-b-PChCL micelles.13 In another study, the PCL block of an 
mPEG-b-PCL copolymer was predicted to be more compatible with 
the poorly water soluble anticancer drug ellipticine, compared to PLA 
(polylactic acid) block of mPEG-b-PLA copolymer using Flory-Huggins 
interaction parameter (sp). In this case, the authors reported a 
higher loading in the more compatible mPEG-b-PCL micelles 
compared to the less compatible mPEG-b-PLA micelles supported the 
prediction made by Flory-Huggins interaction parameter (sp).52 
Experimentally, a higher loading of IND as a model drug was found 
with mPEG-b-PεDL copolymer (6.55 wt%) compared to mPEG-b-PCL 
copolymers (5.39 wt%), which from first principles was not expected. 
However, whilst the drug-polymer interaction is one of the key 
parameters affecting the drug loading into the micelle core, it is 
important to note that neither of the copolymers in our investigation 
possessed any active functional groups that can interact with the 
drug to enhance the drug loading. Thus, we suggest that the 
hydrophobic-hydrophobic interactions between the lipophilic drug 
and hydrophobic blocks of the copolymers were the predominant 
factors for drug-polymer interaction with these systems. Therefore, 
the most probable reason for the increased loading of IND in the 
PεDL copolymers would be the greater disorder of the PεDL core due 
to its amorphous nature, which in turn increased the core volumes 
to provide more space and encapsulate more drug molecules. The 
calculated volume of the PεDL core micelle was ~1.8 times higher 
than the PCL core micelles, providing support for this hypothesis. This 
assertion was reinforced by a recent literature report where the core 
crystallinity of the PCL block was reduced by the incorporation of 
medium chain triglyceride (MCT) in the micelle core to enhance the 
loading of disulfiram (DSF), cabazitaxel (CTX), and TM-2 (a taxane 
derivative).53 
Drug release studies were performed using different controls to 
compare the release profile with IND loaded micelle formulations. 
Control ‘A’ showed that IND transport in solution was not affected by 
the barrier properties of the dialysis membrane. Controls ‘B’ and ‘C’ 
showed that IND was able to interacting with pre-formed micelles 
and this interaction slowed the movement of the drug molecules 
across the dialysis membrane. However, no significant difference 
was observed between control ‘B’ and control ‘C’ which shows that 
the IND was interacting in a similar manner with both of the empty 
micelles. In contrast to the control formulations, the IND loaded 
micelles were able to reduce the release significantly and gave a 
sustained release pattern for 120 h. It is likely that the drug inside the 
micellar cores was present in its protonated form (pKa of 
indomethacin carboxylic acid ~ 4.5). However, the carboxyl group of 
the drug would have been deprotonated after release from the 
polymer micelles to the bulk medium (PBS, pH 7.4). This would have 
led to increased solubilization of IND in the release medium. 
Therefore, the release rate was most dependent on the partition 
coefficient of the IND between the micelle core and release medium 
(PBS, pH 7.4). 
A significant difference in IND release was observed between PEG-b-
PεDL and PEG-b-PCL micelles (P < 0.05, unpaired student’s t-test). 
The PEG-b-PεDL micelles exhibited burst release (34% in 6 h) 
followed by a sustained release phase up to 120 h. On the other 
hand, PEG-b-PCL micelles were able to release the drug over a longer 
period and also the burst release was reduced (25% in 6 h) 
significantly. Around 80% of the drug was released in 72 h and 110 h 
for mPEG-b-PεDL and PEG-b-PCL micelles respectively. This indicates 
that the amorphous core of the mPEG-b-PεDL micelles was not able 
to retain the drug compared to the PCL core. This result was again as 
predicted as the drug molecules can more easily move within the 
mobile chains of PεDL cores compared to those of the semicrystalline 
PCL cores.  
Drug-polymer compatibility predictions from Flory-Huggins theory 
indicated low values of the interaction parameter (χsp) of <5 for all 
the segments of copolymers (mPEG, PεDL and PCL), suggesting that 
the IND should interact with all of the segments in the polymers. 
However, as the relative values of dispersion parameters were 
similar for all the materials in this study [PCL (17.66)>PEG (17.17)> 
PεDL (17.05)], the strength of drug-copolymer interactions were 
predicted to be the same across all polymer segments. Solubility 
differences (∆) showed a lower value for PCL (4.47) compared to 
PεDL (6.30) indicating the higher compatibility of the IND with the 
PCL core. These results were also confirmed by determining 
interaction parameters (χsp). The obtained χsp values implied that 
more IND should encapsulate within PCL core micelles compared to 
PεDL core micelles, but the IND loading study revealed an overall 
higher amount of IND in PεDL core micelles (6.5 wt%) compared to 
PCL core micelles (5.4 wt%). However, determination of the IND 
loading per unit volume of the micelles revealed that the PCL core 
micelle was able to load 1.5 times more drug compared to the PεDL 
cored micelle, illustrating the higher compatibility of IND with the 
PCL core in accordance with the solubility parameter calculations. 
The higher compatibility of the PCL core with IND compared to the 
PεDL core suggested a slower release of drug from the mPEG-b-PCL 
micelles, and this was indeed observed in IND release profiles. Also, 
the slower release can be partly attributed to the semicrystalline 
core in the PCL micelles hence a lower mobility to allow drug 
transport compared to the amorphous PεDL cores. The mPEG block, 
which was a common segment for both of the copolymers, showed 
a low interaction parameter value mPEG (χsp = 3.39). This also 
suggested compatibility between IND and mPEG, although in micellar 
formulations the mPEG block would remain hydrated in the aqueous 
phase and hence would incur enthalpic penalties for association with 
IND. Nevertheless, the burst release in the first 6 h from the micelles 
might have been due to the loose interaction of IND with mPEG at 
core-corona interface. Thus it might be expected that drug molecules 
might not only be in the core but also at the core-corona interface, 
and the association of IND with micelles in the IND transport studies 
with pre-formed empty micelles gave partial backing for this 
assertion. 
Conclusions 
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A successful polymerisation of ε-DL (renewable monomer) was 
described using TBD as an organocatalyst for homopolymer (PεDL) 
and copolymer (mPEG-b-PεDL) synthesis. The properties of the 
copolymer were compared with the structurally similar mPEG-b-PCL 
copolymer. We showed that the copolymers self-assemble in water 
to give non-aggregated nanosized micelles with amorphous (mPEG-
b-PεDL) and semicrystalline cores (mPEG-b-PCL). The amorphous 
core resulted in increased drug loading due to increased core 
volume. However, the determination of loading in term of per unit 
volume of the core illustrated the higher loading in PCL core which 
was in accordance with the Flory-Huggins interaction parameter. A 
sustained release pattern was also demonstrated by PεDL core based 
micelles. The faster release from PεDL core micelles compared to PCL 
core illustrated the effect of core crystallinity on release properties. 
The small size of the micelles combined with sustained release 
characteristics of the mPEG-b-PεDL polymers demonstrate their 
potential as drug delivery vehicles, but further work is needed to 
improve overall drug loading and fine control over release. 
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